Salute e Benessere
Osteoarthritis Market is Predicted to Exhibit Remarkable Growth During the Forecast Period (2025-2034) | DelveInsight
In 2024, approximately diagnosed cases were reported across the 7MM, with projections indicating a rise over the forecast period (2025–2034). The lifetime risk of symptomatic knee osteoarthritis is about , while hip osteoarthritis risk is around .
For years, injecting steroids and hyaluronic acid into the joint space has been a common practice, though its ongoing use has sparked debate in academic circles. Originally approved nearly two decades ago, early intra-articular hyaluronic acid treatments required up to five injections. Reducing this to three injections typically eases the burden.
Today, several FDA-approved single-injection hyaluronic acid products are available, proven to enhance mobility and reduce pain for up to 26 weeks post-treatment. These safer, more effective options with fewer injections may also lower long-term healthcare costs.
Learn more about the osteoarthritis treatment market @
The FDA has approved several hyaluronate products, including , and . , developed by , is the first and only extended-release intra-articular treatment for knee osteoarthritis pain, approved by the US FDA in October 2017 .
, developed by , combines hyaluronic acid and diclofenac (an anti-inflammatory) using Seikagaku's proprietary technology. , for knee osteoarthritis pain, follows their earlier products, .
, from , is a sterile, non-pyrogenic viscoelastic hydrogel in a single-use syringe, approved by the US FDA in August 2015 for knee osteoarthritis. , by , is a sterile, gel-like product with highly purified hyaluronan, relaunched in 2022 and marketed with Arthrex in the US.
, including , are designed to relieve symptoms and inflammation associated with osteoarthritis.
Find out more on the osteoarthritis drugs market @
At present, osteoarthritis treatments include NSAIDs, opioids, intra-articular corticosteroids, intra-articular hyaluronic acid, and other options. Despite NSAIDs' gastrointestinal and cardiovascular risks and acetaminophen's limited efficacy, both are commonly prescribed. In the EU4 and the UK, NSAID use is higher than in the US, though opioid use is increasing. Several companies are working on new osteoarthritis therapies that, if approved, could slow disease progression and potentially offer a cure.
The emerging market comprises novel classes such as TRPV1 receptor agonists, pan-CLK/DYRK modifiers, stem cell therapies, GLP-1 receptor agonists, Cyclo-oxygenase 2 inhibitors, and others. Among the potential therapies for managing osteoarthritis symptoms, (Paradigm Biopharmaceuticals), (BioSenic), (Grünenthal), (Centrexion Therapeutics), and (Amzell) emerged as the top five contenders.
Discover which therapies are expected to grab the major osteoarthritis therapeutics market @
, a semi-synthetic drug derived from European beech tree wood chips, exhibits anti-inflammatory and tissue-regenerative properties alongside mild anti-thrombotic effects. In April 2022 , the US FDA granted to ZILOSUL for osteoarthritis treatment. Paradigm secured European regulatory and ethics approvals in March 2023 for the global pivotal PARA_OA_002 clinical trial. By April 2024 , Paradigm submitted critical documents to the US FDA to advance its Phase III osteoarthritis clinical program.
, developed by , is a next-generation intra-articular injectable for knee osteoarthritis pain. In March 2023 , BioSenic reassessed its Phase III trial results, with post-hoc analysis revealing JTA-004's superior pain relief compared to placebo and an active comparator in patients with severe, inflammatory knee osteoarthritis. BioSenic is now seeking partnerships to further develop JTA-004 based on these findings.
, a high-potency, odorless, noninvasive topical gel with 3.06% diclofenac sodium, is applied directly to the knee. Approved by the FDA and EMA, this proprietary technology completed a successful four-week Phase II/III efficacy study in 440 patients across the US, Denmark , and the Czech Republic . It is currently under evaluation in Phase III for knee osteoarthritis treatment.
Discover more about osteoarthritis drug development @
The anticipated launch of these emerging therapies for osteoarthritis are poised to transform the market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the osteoarthritis market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
DelveInsight estimates that the US osteoarthritis treatment market size is expected to grow from
in 2024 at a significant CAGR by 2034. In 2024, Opioids captured the highest osteoarthritis treatment market size by therapies, i.e., around
in the US. The growth of the osteoarthritis market is driven by an aging global population and rising prevalence of the condition. Increasing demand for innovative treatments, such as biologics, injectables, and topical therapies, further fuels osteoarthritis market expansion.
DelveInsight's latest published market report, titled as will help you to discover which market leader is going to capture the largest market share. The report provides comprehensive insights into the osteoarthritis country-specific treatment guidelines, patient pool analysis, and epidemiology forecast to help understand the key opportunities and assess the market's underlying potential. The osteoarthritis market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
The report provides an edge while developing business strategies by understanding trends shaping and driving the 7MM osteoarthritis market. Highlights include:
Download this osteoarthritis market report to assess the epidemiology forecasts, understand the patient journeys, know KOLs' opinions about the upcoming treatment paradigms, and determine the factors contributing to the shift in the osteoarthritis market. Also, stay abreast of the mitigating factors to improve your market position in the osteoarthritis therapeutic space.
report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, and the osteoarthritis epidemiology trends.
report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key osteoarthritis companies, including among others.
report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key knee osteoarthritis companies, including among others.
report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key erosive hand osteoarthritis companies, including among others.
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve
Shruti Thakur
info@delveinsight.com
+14699457679
Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/osteoarthritis-market-is-predicted-to-exhibit-remarkable-growth-during-the-forecast-period-20252034--delveinsight-302484832.html